CSL vs GRFS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: GRFS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CSL and GRFS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CSL and GRFS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Carlisle Companies Incorporated (NYSE: CSL) is a diversified manufacturer that, after years of portfolio reshaping, has become a focused supplier of building-envelope products that make commercial and residential buildings more energy efficient. It operates through two segments: Carlisle Construction Materials (CCM), which makes single-ply roofing membranes (EPDM rubber, TPO, and PVC), polyiso insulation, and metal roofing and wall systems, and Carlisle Weatherproofing Technologies (CWT), which makes waterproofing, air and vapor barriers, sealants, spray polyurethane foam, coatings, and related moisture-protection products. The company earns most of its revenue from commercial construction, and within that, a large share comes from re-roofing (replacing aging roofs), which is more stable than new construction because roofs wear out on a predictable cycle regardless of the economy.

Full CSL guide

Grifols, S.A. is a Spanish healthcare company founded in Barcelona in 1909 and one of the three dominant players in the global blood-plasma industry, alongside CSL and Takeda. It collects human plasma through a large network of donation centers (heavily concentrated in the United States) and fractionates it into therapies, most importantly immunoglobulins (IVIG and subcutaneous Ig) used for immune deficiencies and neurological conditions, plus albumin, alpha-1 antitrypsin, and clotting factors. The business also includes a diagnostics division (blood typing, transfusion screening) and a bio-supplies arm. Revenue comes from selling these plasma-derived medicines to hospitals, specialty pharmacies, and health systems worldwide, with the immunoglobulin franchise the single largest and fastest-growing driver. Grifols trades on the Spanish exchanges under Class A (GRF) and non-voting Class B (GRF.P) shares, and in the US as ADRs under the ticker GRFS.

Full GRFS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CSL drivers: Commercial re-roofing replacement cycle; Margin expansion and pure-play focus.
• GRFS drivers: Immunoglobulin demand and volume growth; Margin recovery from lower cost-per-liter.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Carlisle's end markets are cyclical: commercial and residential construction activity is sensitive to interest rates, credit availability, and the broader economy, and a downturn in construction spending would pressure volumes. For GRFS, grifols carries a heavy debt load, with leverage still above 4x, so its equity value is sensitive to interest rates, refinancing terms, and any stumble in cash generation.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CSL if you believe its drivers more; GRFS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CSL and GRFS guides.

CSL. Carlisle trades around a low-20s trailing P/E, roughly in line with its own long-term historical median and typical for a high-margin, cash-generative industrial. Because a large part of its earnings power comes from resilient re-roofing demand and steady margin expansion, investors tend to focus on adjusted EBITDA margin, free cash flow, and the pace of buybacks rather than raw revenue growth, which can be lumpy with weather and construction cycles. The Q1 2026 revenue dip was driven largely by poor winter weather that limited roofing installation, while margins still expanded and management reaffirmed full-year guidance for low-single-digit revenue growth.

GRFS. As of July 2026 Grifols trades at a discount to plasma peers like CSL, reflecting its higher leverage and the residual governance overhang rather than weak operations. On enterprise-value terms the shares look inexpensive against roughly EUR 1.8 billion of adjusted EBITDA, but the large net-debt position means most of that enterprise value still sits with lenders, which is exactly why deleveraging is the key equity lever. Analysts generally rate the ADR in the Hold-to-Moderate-Buy range with price targets clustered around $10 to $12.50.

Headline figures (approximate, July 2026): CSL shows revenue (ttm) ~$5.0 billion, q1 2026 revenue ~$1.05 billion (down ~4% year over year), q1 2026 adjusted eps ~$3.63 (up ~1% year over year), q1 2026 adjusted ebitda margin ~22.3% (up ~50 bps); GRFS shows revenue (fy 2025) ~EUR 7.5 billion (~$8.2 billion), adjusted ebitda (fy 2025) ~EUR 1.8 billion (~24% margin), net profit (fy 2025) ~EUR 402 million (more than doubled YoY), q1 2026 revenue ~EUR 1.7 billion (+3.3% cc).

CSL and GRFS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CSL and GRFS exposure against your real portfolio. It is not an investment adviser.